



Pascal Bioscience Inc.
280 7th Avenue East
Vancouver, BC V5T 0B4
www.pascalbiosciences.com

Pascal Announces Extension and Repricing of Share Purchase Warrants

VANCOUVER, BRITISH COLUMBIA, February 25, 2019 - Pascal Biosciences Inc. (TSX.V: PAS) (the "Company"), a Vancouver-based biotechnology company, wishes to announce that it will make an application to the TSX Venture Exchange Inc. (the "Exchange") to (i) reprice a total of 9,380,000 share purchase warrants (the "Warrants") to an exercise price of \$0.285 per Warrant, down from \$0.60 per Warrant, and (ii) extend the exercise date of the Warrants until June 12, 2019. The Warrants were issued with an original term of 12 months in connection with the closing of a private placement financing as announced by the Company on February 23, 2018. In accordance with the Exchange policy 4.1, the Warrants will be subject to an acceleration provision that should the closing price of the common shares of the Company on the Exchange be \$0.36 or higher for ten consecutive trading days, the Company must accelerate the expiry of the Warrants to the date that is 30 days from the date of notice by the Company announcing the exercise of the acceleration right.

No Warrants are held by the insiders of the Company.

On Behalf of the Board of Directors
Patrick W. Gray, President & CEO

Company Contact:

Dr. Patrick Gray
Tel: 1-206-650-6765

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”

NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES